Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

Lam, S. W.; de Groot, S. M.; Honkoop, A. H.; Jager, A.; ten Tije, A. J.; Bos, M. M. E. M.; Linn, S. C.; van den Bosch, J.; Kroep, J. R.; Braun, J. J.; van Tinteren, H.; Boven, E.

Published in

Elsevier, European Journal of Cancer, 18(50), p. 3077-3088, 2014

DOI: 10.1016/j.ejca.2014.10.008

Tools

Export citation

Search in Google Scholar

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

Journal article published in 2014 by S. W. Lam, S. M. de Groot, A. H. Honkoop, A. Jager, A. J. ten Tije, M. M. E. M. Bos, S. C. Linn, J. van den Bosch

, J. R. Kroep, J. J. Braun, H. van Tinteren

, E. Boven

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial